IP Library Granted Patent US 8,490,795
Granted Patent B2
US 8,490,795 · App. 13/015,490 · Granted Jul 23, 2013

Container and method for facilitating disposal of unused pharmaceutical product

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,490,795
App. No.
13/015,490
Granted
Jul 23, 2013
Kind
B2
Abstract

Containers and methods for disposing unused pharmaceutical product are disclosed. Each container ( 100, 200, 300 ) may include a container body ( 104, 204, 304 ) with an internal chamber ( 116, 216, 316 ) for storing pharmaceutical product, along with a cover ( 124, 224, 324 ) for selectively limiting access to the chamber ( 116, 216, 316 ). An encapsulation component ( 128, 228, 328 ) may be selectively disposable within the chamber ( 116, 216, 316 ), and may be operable to encapsulate the pharmaceutical product within the container ( 100, 200, 300 ). For instance, the encapsulation component ( 128, 228, 328 ) may melt and/or flow into contact with the pharmaceutical product and thereafter solidify to encapsulate the pharmaceutical product. The encapsulation component ( 128, 228, 328 ) may melt and thereafter solidify between the cover ( 124, 224, 324 ) and shell ( 104, 204, 304 ) to limit removal of the cover ( 124, 224, 324 ) from the shell ( 104, 204, 304 ).

Claims (22)

1. A pharmaceutical product container, comprising:

a container body comprising a first melting temperature;

a chamber, wherein at least part of said chamber is within said container body;

pharmaceutical product within said chamber, wherein all of said pharmaceutical product within said chamber is unused pharmaceutical product;

an access member movable between open and closed positions relative to said container body, wherein disposing said access member in said open position provides access to said pharmaceutical product within said chamber, and wherein disposing said access member in said closed position encloses said pharmaceutical product within said chamber; and

a heat-activated encapsulation material that is separately incorporated on a portion of said access member that is able to interface with said chamber, wherein said heat-activated encapsulation material comprises a second melting temperature that is less than said first melting temperature, wherein heating said container to at least said second melting temperature activates said heat-activated encapsulation material, and wherein said activated encapsulation material both bonds said access member to said container body and at least partially encapsulates said pharmaceutical product.

2. The container of claim 1 , wherein said heat-activated encapsulation material is selected from the group consisting of plastic, wax, and adhesive.

3. The container of claim 1 , wherein said pharmaceutical product comprises at least one of a pill, capsule, caplet, tablet, and a patch.

4. The container of claim 1 , wherein said pharmaceutical product comprises a plurality of doses.

5. The container of claim 1 , wherein disposing said access member in said open position exposes an entirety of said pharmaceutical product within said container body.

6. The container of claim 1 , wherein heating said container to at least said second melting temperature does not melt said container body.

7. A pharmaceutical product container, comprising:

a container body comprising a first melting temperature;

pharmaceutical product within said container body, wherein all of said pharmaceutical product within said container body is unused pharmaceutical product; and

an access member movable between open and closed positions relative to said container body, wherein disposing said access member in said open position provides access to said pharmaceutical product within said container body, and wherein disposing said access member in said closed position encloses said pharmaceutical product within said container body, wherein said access member comprises:

an access member body having an inside surface operable to face towards said pharmaceutical product and an outside surface operable to face away from said container body; and

a heat-activated encapsulation material that is disposed on said inside surface of said access member body, wherein said heat-activated encapsulation material comprises a second melting temperature that is less than said first melting temperature, wherein heating said container to at least said second melting temperature activates said heat-activated encapsulation material, and wherein said activated encapsulation material both bonds said access member body to said container body and at least partially encapsulates said pharmaceutical product.

8. The container of claim 7 , wherein said heat-activated encapsulation material is selected from the group consisting of plastic, wax, and adhesive.

9. The container of claim 7 , wherein said pharmaceutical product comprises at least one of a pill, capsule, caplet, tablet, and a patch.

10. The container of claim 7 , wherein said pharmaceutical product comprises a plurality of doses.

11. The container of claim 7 , wherein disposing said access member in said open position exposes an entirety of said pharmaceutical product within said container body.

12. The container of claim 7 , wherein heating said container to at least said second melting temperature does not melt said container body.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →